NBIX vs. ABT
Compare and contrast key facts about Neurocrine Biosciences, Inc. (NBIX) and Abbott Laboratories (ABT).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NBIX or ABT.
Correlation
The correlation between NBIX and ABT is 0.23, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
NBIX vs. ABT - Performance Comparison
Key characteristics
NBIX:
0.33
ABT:
0.32
NBIX:
0.64
ABT:
0.59
NBIX:
1.10
ABT:
1.07
NBIX:
0.41
ABT:
0.23
NBIX:
0.90
ABT:
0.72
NBIX:
12.31%
ABT:
8.05%
NBIX:
33.36%
ABT:
17.81%
NBIX:
-97.21%
ABT:
-45.66%
NBIX:
-11.88%
ABT:
-15.93%
Fundamentals
NBIX:
$13.84B
ABT:
$196.50B
NBIX:
$3.75
ABT:
$3.29
NBIX:
36.45
ABT:
34.43
NBIX:
0.32
ABT:
2.19
NBIX:
$2.24B
ABT:
$41.22B
NBIX:
$2.20B
ABT:
$22.55B
NBIX:
$614.00M
ABT:
$10.76B
Returns By Period
In the year-to-date period, NBIX achieves a 2.43% return, which is significantly lower than ABT's 4.18% return. Over the past 10 years, NBIX has outperformed ABT with an annualized return of 19.31%, while ABT has yielded a comparatively lower 11.39% annualized return.
NBIX
2.43%
13.29%
0.66%
12.18%
4.22%
19.31%
ABT
4.18%
-4.02%
6.55%
6.77%
7.21%
11.39%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NBIX vs. ABT - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Neurocrine Biosciences, Inc. (NBIX) and Abbott Laboratories (ABT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
NBIX vs. ABT - Dividend Comparison
NBIX has not paid dividends to shareholders, while ABT's dividend yield for the trailing twelve months is around 1.96%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NBIX Neurocrine Biosciences, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
ABT Abbott Laboratories | 1.96% | 1.85% | 1.71% | 1.28% | 1.32% | 1.47% | 1.55% | 1.86% | 2.71% | 2.14% | 1.95% | 1.46% |
Drawdowns
NBIX vs. ABT - Drawdown Comparison
The maximum NBIX drawdown since its inception was -97.21%, which is greater than ABT's maximum drawdown of -45.66%. Use the drawdown chart below to compare losses from any high point for NBIX and ABT. For additional features, visit the drawdowns tool.
Volatility
NBIX vs. ABT - Volatility Comparison
Neurocrine Biosciences, Inc. (NBIX) has a higher volatility of 7.28% compared to Abbott Laboratories (ABT) at 3.32%. This indicates that NBIX's price experiences larger fluctuations and is considered to be riskier than ABT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
NBIX vs. ABT - Financials Comparison
This section allows you to compare key financial metrics between Neurocrine Biosciences, Inc. and Abbott Laboratories. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities